HODGKIN LYMPHOMA S1826

Study #S1826

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Back To Clinical Trials